bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell TransfusionsBusiness Wire • 08/17/22
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell TransfusionsBusiness Wire • 08/17/22
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug DearthZacks Investment Research • 08/15/22
5 Sizzling Well-Known Stocks Rated Buy Trading Under $10 With Big Upside Potential24/7 Wall Street • 08/13/22
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational ProgressBusiness Wire • 08/04/22
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/01/22
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This WeekThe Motley Fool • 07/08/22
Bluebird (BLUE) Surges 18%: Is This an Indication of Further Gains?Zacks Investment Research • 07/06/22